# ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

> **NCT03922555** · PHASE1 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Neurological Cancer

## Interventions

- **DRUG:** ASTX727

## Key facts

- **NCT ID:** NCT03922555
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-12
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03922555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03922555, "ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03922555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*